Epidemiology, diagnosis and treatment of Clostridium difficile infection

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 12, 2012, Pages 1405-1423

  Bassetti, Matteo ^a   Villa, Giovanni ^a   Pecori, Davide ^a   Arzese, Alessandra ^a,b   Wilcox, Mark ^a,c  

^a S Maria Hospital   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Clostridium difficile; diagnosis; diarrhea; epidemiology; fidaxomicin; metronidazole; treatment; vancomycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BACTERIAL ANTIGEN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID; FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN; MACROLIDE; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFAXIMIN; SYNSORB 90; TIGECYCLINE; TOLEVAMER; TOXOID; TRISACCHARIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGEN DETECTION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BIOLOGICAL THERAPY; CANADA; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON LAVAGE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY TEST; DIARRHEA; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FECAL TRANSPLANTATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; INCIDENCE; INTENTION TO TREAT ANALYSIS; INTESTINE FLORA; LACTOBACILLUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROTEIN SYNTHESIS INHIBITION; PROTEUS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RIBOTYPING; RISK FACTOR; SACCHAROMYCES BOULARDII; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TOXIN ANALYSIS; UNITED STATES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84871463724     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.135     Document Type: Review

References (183)

1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7(7), 526-536 (2009).
2. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342(6), 390-397 (2000). (Pubitemid 30084537)
3. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351(9103), 633-636 (1998). (Pubitemid 28098446)
4. Bartlett JG. Clinical practice. Antibioticassociated diarrhea. N. Engl. J. Med. 346(5), 334-339 (2002).
5. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 122(6), 1266-1270 (2008).
6. Rouphael NG, O'Donnell JA, Bhatnagar J et al. Clostridium difficile-associated diarrhea: An emerging threat to pregnant women. Am. J. Obstet. Gynecol. 198(6), 635.e1-635.e6 (2008).
7. Pépin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 171(5), 466-472 (2004). (Pubitemid 39179608)
8. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications. Ann. Surg. 235(3), 363-372 (2002). (Pubitemid 34183887)
9. Kuijper EJ, Barbut F, Brazier JS et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 13(31,)18942 (2008).
10. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6), 2-18 (2006). (Pubitemid 44362038)
11. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23(3), 529-549 (2010).
12. Kuijper EJ, Coignard B, Brazier JS et al. Update Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill. 12(6), E1-E2 (2007).
13. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I; European Study Group on Clostridium difficile (ESGCD).Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin. Microbiol. Infect. 13(11), 1048-1057 (2007). (Pubitemid 47553515)
14. Bauer MP, Notermans DW, van Benthem BH et al.; ECDIS Study Group. Clostridium difficile infection in Europe: A hospital-based survey. Lancet 377(9759), 63-73 (2011).
15. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40(11), 1586-1590 (2005). (Pubitemid 40720807)
16. Pépin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41(9), 1254-1260 (2005). (Pubitemid 41532667)
17. Weiss K. Clostridium difficile and fluoroquinolones: Is there a link? Int. J. Antimicrob. Agents 33(Suppl. 1), S29-S32 (2009).
18. Niyogi SK, Bhattacharya SK, Dutta P et al. Prevalence of Clostridium difficile in hospitalised patients with acute diarrhoea in Calcutta. J. Diarrhoeal Dis. Res. 9(1), 16-19 (1991).
19. Gupta U, Yadav RN. Clostridium difficile in hospital patients. Indian J. Med. Res. 82, 398-401 (1985).
20. Ayyagari A, Sharma P, Venkateswarlu, Mehta S, Agarwal KC. Prevalence of Clostridium difficile in pseudomembranous and antibiotic-associated colitis in north India. J. Diarrhoeal Dis. Res. 4(3), 157-160 (1986).
21. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353(23), 2433-2441 (2005). (Pubitemid 41770164)
22. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366(9491), 1079-1084 (2005). (Pubitemid 41338761)
23. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J. Antimicrob. Chemother. 60(1), 83-91 (2007). (Pubitemid 47073280)
24. Geric B, Johnson S, Gerding DN, Grabnar M, Rupnik M. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J. Clin. Microbiol. 41(11), 5227-5232 (2003). (Pubitemid 37429946)
25. Gonçalves C, Decré D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J. Clin. Microbiol. 42(5), 1933-1939 (2004). (Pubitemid 38637804)
26. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56(9), 2299-2306 (1988).
27. Perelle S, Gibert M, Bourlioux P, Corthier G, Popoff MR. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect. Immun. 65(4), 1402-1407 (1997). (Pubitemid 27146631)
28. Carter GP, Douce GR, Govind R et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 7(10), e1002317 (2011).
29. Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47(9), 1162-1170 (2008).
30. Stabler RA, He M, Dawson L et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 10(9), R102 (2009).
31. Akerlund T, Persson I, Unemo M et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J. Clin. Microbiol. 46(4), 1530-1533 (2008). (Pubitemid 351563610)
32. Spigaglia P, Barbanti F, Mastrantonio P et al.; European Study Group on Clostridium difficile (ESGCD). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J. Med. Microbiol. 57(Pt 6), 784-789 (2008). (Pubitemid 351842073)
33. Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J. Antimicrob. Chemother. 58(6), 1264-1267 (2006). (Pubitemid 44884150)
34. Freeman J, Fawley WN, Best E, Verity P, Parnell P, Wilcox MH. Clustering of Clostridium difficile isolates with reduced susceptibility to metronidazole or vancomycin. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2011 (Abstract C2-1807).
35. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin. Infect. Dis. 47(1), 63-65 (2008). (Pubitemid 351920589)
36. Purdell J, Fawley W, Freeman J, Wilcox MH. Investigation of outcome in cases of Clostridium difficile infection due to isolates with reduced susceptibility to metronidazole. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, 7-10 May 2011 (Abstract 0499).
37. Gerber M, Walch C, Löffler B, Tischendorf K, Reischl U, Ackermann G. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J. Med. Microbiol. 57(Pt 6), 776-783 (2008). (Pubitemid 351842072)
38. Saxton K, Baines SD, Freeman J, O'Connor R, Wilcox MH. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob. Agents Chemother. 53(2), 412-420 (2009).
39. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J. Antimicrob. Chemother. 52(1), 96-102 (2003). (Pubitemid 36850092)
40. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J. Antimicrob. Chemother. 55(6), 974-982 (2005). (Pubitemid 40883184)
41. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 58(5), 1062-1065 (2006).
42. Centers for Disease Control and Prevention (CDC).Severe Clostridium difficile-associated disease in populations previously at low risk Y four states. Morb. Mortal. Wkly Rep. 54(47), 1201-1205 (2005).
43. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A caseYcontrol study of community-associated Clostridium difficile infection. J. Antimicrob. Chemother. 62(2), 388-396 (2008). (Pubitemid 351984787)
44. al Saif N, Brazier JS. The distribution of Clostridium difficile in the environment of South Wales. J. Med. Microbiol. 45(2), 133-137 (1996). (Pubitemid 26291483)
45. Hensgens MP, Keessen EC, Squire MM et al.; European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD).Clostridium difficile infection in the community: A zoonotic disease? Clin. Microbiol. Infect. 18(7), 635-645 (2012).
46. Rupnik M. Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin. Microbiol. Infect. 13(5), 457-459 (2007). (Pubitemid 46563496)
47. Wilcox MH, Shetty N, Fawley WN et al. Changing Epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55(8), 1056-1063 (2012).
48. Goorhuis A, Debast SB, van Leengoed LA et al. Clostridium difficile PCR ribotype 078: An emerging strain in humans and in pigs? J. Clin. Microbiol. 46(3), 1157; author reply 1158 (2008). (Pubitemid 351380026)
49. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J. Antimicrob. Chemother. 66(9), 2168-2174 (2011).
50. Price J, Cheek E, Lippett S et al. Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clin. Microbiol. Infect. 16(8), 1297-1302 (2010).
51. Merrigan MM, Sambol SP, Johnson S, Gerding DN. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188(12), 1922-1927 (2003). (Pubitemid 38064879)
52. Merrigan M, Sambol S, Johnson S, Gerding DN. Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe 9(2), 91-95 (2003). (Pubitemid 36808836)
53. Johnson S, Samore MH, Farrow KA et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341(22), 1645-1651 (1999).
54. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 179(8), 767-772 (2008).
55. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353(23), 2442-2449 (2005). (Pubitemid 41770165)
56. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficileassociated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26(3), 273-280 (2005). (Pubitemid 40445086)
57. Gaynes R, Rimland D, Killum E et al. Outbreak of Clostridium difficile infection in a long-term care facility: Association with gatifloxacin use. Clin. Infect. Dis. 38(5), 640-645 (2004). (Pubitemid 38333858)
58. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and caseYcontrol studies. CMAJ 171(1), 33-38 (2004). (Pubitemid 38925116)
59. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357(9251), 189-193 (2001). (Pubitemid 32108091)
60. Miller M, Gravel D, Mulvey M et al. Health care-associated Clostridium difficile infection in Canada: Patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50(2), 194-201 (2010).
61. Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170(9), 784-790 (2010).
62. Best EL, Fawley WN, Parnell P, Wilcox MH. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin. Infect. Dis. 50(11), 1450-1457 (2010). spread of C. difficile spores from patients with symptomatic C. difficile infection.
63. Best EL, Sandoe JA, Wilcox MH. Potential for aerosolization of Clostridium difficile after flushing toilets: The role of toilet lids in reducing environmental contamination risk. J. Hosp. Infect. 80(1), 1-5 (2012).
64. von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M. Large clostridial cytotoxins Y a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol. 4(10), 375-382 (1996). (Pubitemid 26325127)
65. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J. Med. Microbiol. 57(Pt 6), 685-689 (2008). (Pubitemid 351842058)
66. Barbut F, Decré D, Lalande V et al. Clinical features of Clostridium difficileassociated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J. Med. Microbiol. 54(Pt 2), 181-185 (2005). (Pubitemid 40868005)
67. Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. N. Y. Acad. Sci. 915, 347-356 (2000). (Pubitemid 32059401)
68. Freeman J, Baines SD, Jabes D, Wilcox MH. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycininduced Clostridium difficile infection. J. Antimicrob. Chemother. 56(4), 717-725 (2005). (Pubitemid 41487774)
69. Bartlett JG. Antibiotic-associated diarrhea. Clin. Infect. Dis. 15(4), 573-581 (1992).
70. Cohen SH, Gerding DN, Johnson S et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).Infect. Control Hosp. Epidemiol. 31(5), 431-455 (2010).
71. Alfa MJ, Kabani A, Lyerly D et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38(7), 2706-2714 (2000). (Pubitemid 30485154)
72. Sambol SP, Merrigan MM, Lyerly D, Gerding DN, Johnson S. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect. Immun. 68(10), 5480-5487 (2000).
73. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J. Clin. Microbiol. 40(9), 3470-3475 (2002). (Pubitemid 34977470)
74. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 36(8), 2240-2247 (1998). (Pubitemid 28324074)
75. Van de Berg RJ, Claas EC, Oyib DH et al. Characterization of a toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J. Cin. Microbiol. 42, 1035-1041 (2004). (Pubitemid 38332822)
76. Kato H, Kato N, Watanabe K et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J. Clin. Microbiol. 36(8), 2178-2182 (1998). (Pubitemid 28324061)
77. Cohen SH, Tang YJ, Silva J Jr. Analysis of the pathogenicity locus in Clostridium difficile strains. J. Infect. Dis. 181(2), 659-663 (2000). (Pubitemid 30131836)
78. Limaye AP, Turgeon DK, Cookson BT, Fritsche TR. Pseudomembranous colitis caused by a toxin A(-) B(+)strain of Clostridium difficile. J. Clin. Microbiol. 38(4), 1696-1697 (2000). (Pubitemid 30216720)
79. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 159(2), 340-343 (1989). (Pubitemid 19049377)
80. Louie TJ, Miller MA, Mullane KM et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364(5), 422-431 (2011).
81. DuPont HL. The search for effective treatment of Clostridium difficile infection. N. Engl. J. Med. 364(5), 473-475 (2011).
82. Fenner L, Widmer AF, Goy G, Rudin S, Frei R. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J. Clin. Microbiol. 46(1), 328-330 (2008).
83. Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C.Diff Quik Check Complete assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid,simple diagnosis of Clostridium difficile disease. J. Clin. Microbiol. 48, 2082-2086 (2010).
84. Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J. Clin. Microbiol. 48(2), 606-608 (2010).
85. Wilkins TD, Lyerly DM. Clostridium difficile testing: After 20 years, still challenging. J. Clin. Microbiol. 41(2), 531-534 (2003). (Pubitemid 36184156)
86. Larson HE, Price AB, Honour P, Borriello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1(8073), 1063-1066 (1978). (Pubitemid 8356366)
87. George WL, Sutter VL, Citron D, Finegold SM. Selective and differential medium for isolation of Clostridium difficile. J. Clin. Microbiol. 9(2), 214-219 (1979). (Pubitemid 9123787)
88. Wilson KH, Kennedy MJ, Fekety FR. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15(3), 443-446 (1982). (Pubitemid 12178880)
89. Chang TW, Lauermann M, Bartlett JG. Cytotoxicity assay in antibiotic-associated colitis. J. Infect. Dis. 140(5), 765-770 (1979). (Pubitemid 10214201)
90. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: Its disease and toxins. Clin. Microbiol. Rev. 1(1), 1-18 (1988).
91. Planche T, Aghaizu A, Holliman R et al. Diagnosis of Clostridium difficile infection by toxin detection kits: A systematic review. Lancet Infect. Dis. 8(12), 777-784 (2008).
92. al-Barrak A, Embil J, Dyck B et al. An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can. Commun. Dis. Rep. 25(7), 65-69 (1999).
93. McGowan K, Kader HA. Clostridium difficile infection in children. Infect. Immun. 23, 211-219 (1999).
94. Mehlig M, Moos M, Braun V, Kalt B, Mahony DE, von Eichel-Streiber C. Variant toxin B and a functional toxin A produced by Clostridium difficile C34. FEMS Microbiol. Lett. 198(2), 171-176 (2001). (Pubitemid 32411561)
95. Carman RJ, Wickham KN, Chen L et al. Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes. J. Clin. Microbiol. 50(4), 1425-1426 (2012).
96. Willis DH, Kraft JA. Confirmation that the latex-reactive protein of Clostridium difficile is a glutamate dehydrogenase. J. Clin. Microbiol. 30(5), 1363-1364 (1992).
97. Altaie SS, Meyer P, Dryja D. Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J. Clin. Microbiol. 32(1), 51-53 (1994). (Pubitemid 24016781)
98. Barbut F, Lalande V, Daprey G et al. Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases. Eur. J. Clin. Microbiol. Infect. Dis. 19(6), 481-484 (2000). (Pubitemid 30458662)
99. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320(4), 204-210 (1989). (Pubitemid 19034145)
100. Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SL. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 147(Pt 2), 439-447 (2001). (Pubitemid 32156820)
101. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J. Clin. Microbiol. 37(2), 461-463 (1999). (Pubitemid 29056430)
102. Fawley WN, Wilcox MH; Clostridium difficile Ribotyping Network for England and Northern Ireland. An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotype. J. Clin. Microbiol. 49(12), 4333-4337 (2011).
103. Killgore G, Thompson A, Johnson S et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: Restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J. Clin. Microbiol. 46(2), 431-437 (2008). (Pubitemid 351231282)
104. Lemee L, Dhalluin A, Testelin S et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J. Clin. Microbiol. 42(12), 5710-5714 (2004). (Pubitemid 39664357)
105. Samie A, Obi CL, Franasiak J et al. PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South Africa. Am. J. Trop. Med. Hyg. 78(4), 577-585 (2008). (Pubitemid 351845160)
106. Eyre DW, Golubchik T, Gordon NC et al. A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open 2(3), 001124 (2012).
107. Walker AS, Eyre DW, Wyllie DH et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med. 9(2), 001124 (2012).
108. Arzese A, Trani G, Riul L, Botta GA. Rapid polymerase chain reaction method for specific detection of toxigenic Clostridium difficile. Eur. J. Clin. Microbiol. Infect. Dis. 14(8), 716-719 (1995).
109. Alonso R, Muñoz C, Gros S, García de Viedma D, Peláez T, Bouza E. Rapid detection of toxigenic Clostridium difficile from stool samples by a nested PCR of toxin B gene. J. Hosp. Infect. 41(2), 145-149 (1999). (Pubitemid 29084009)
110. Peterson LR, Manson RU, Paule SM et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin. Infect. Dis. 45(9), 1152-1160 (2007). (Pubitemid 47580313)
111. Huang H, Weintraub A, Fang H, Nord CE. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. J. Clin. Microbiol. 47(11), 3729-3731 (2009).
112. Novak-Weekley SM, Marlowe EM, Miller JM et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J. Clin. Microbiol. 48(3), 889-893 (2010).
113. Tenover FC, Novak-Weekley S, Woods CW et al. Impact of strain type on detection of toxigenic Clostridium difficile: Comparison of molecular diagnostic and enzyme immunoassay approaches. J. Clin. Microbiol. 48(10), 3719-3724 (2010).
114. Babady NE, Stiles J, Ruggiero P et al. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J. Clin. Microbiol. 48(12), 4519-4524 (2010).
115. Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J. Clin. Microbiol. 48(6), 2082-2086 (2010).
116. Zidaric V, Kevorkijan BK, Oresic N, Janezic S, Rupnik M. Comparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratory. J. Med. Microbiol. 60(Pt 8), 1131-1136 (2011).
117. Pancholi P, Kelly C, Raczkowski M, Balada-Llasat JM. Detection of toxigenic Clostridium difficile: Comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J. Clin. Microbiol. 50(4), 1331-1335 (2012).
118. Norén T, Alriksson I, Andersson J, Akerlund T, Unemo M. Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard. J. Clin. Microbiol. 49(2), 710-711 (2011).
119. Lalande V, Barrault L, Wadel S, Eckert C, Petit JC, Barbut F. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J. Clin. Microbiol. 49(7), 2714-2716 (2011).
120. Rupnik M. Heterogeneity of large clostridial toxins: Importance of Clostridium difficile toxinotypes. FEMS Microbiol. Rev. 32(3), 541-555 (2008). (Pubitemid 351538749)
121. Kozak K, Elagin V, Norén T, Unemo M. Targeting the tcdA gene: Is this appropriate for detection of A and/or B Clostridium difficile toxin-producing strains? J. Clin. Microbiol. 49(6), 2383; author reply 2383-2383; author reply 2384 (2011).
122. Deshpande A, Pasupuleti V, Rolston DD et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: A meta-analysis. Clin. Infect. Dis. 53(7), e81-e90 (2011).
123. Valiquette L, Pépin J, Do XV et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin. Infect. Dis. 49(4), 554-560 (2009).
124. Wee B, Poels JA, McCafferty IJ, Taniere P, Olliff J. A description of CT features of Clostridium difficile infection of the small bowel in four patients and a review of literature. Br. J. Radiol. 82(983), 890-895 (2009).
125. Burkart NE, Kwaan MR, Shepela C et al. Indications and Relative Utility of Lower Endoscopy in the Management of Clostridium difficile Infection. Gastroenterol. Res. Pract. 2011, 626582 (2011).
126. Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI).Clin. Microbiol. Infect. 15(12), 1067-1079 (2009).
127. Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 2(8358), 1043-1046 (1983). (Pubitemid 14235361)
128. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22(5), 813-818 (1996). (Pubitemid 26255600)
129. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45(3), 302-307 (2007). (Pubitemid 47101025)
130. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin. Infect. Dis. 42(6), 758-764 (2006). (Pubitemid 43363928)
131. Kelly CP, LaMont JT. Clostridium difficile Y more difficult than ever. N. Engl. J. Med. 359(18), 1932-1940 (2008).
132. Koo HL, DuPont HL. Rifaximin: A unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroenterol. 26(1), 17-25 (2010).
133. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44(6), 846-848 (2007). (Pubitemid 46365312)
134. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15(6), 290-291 (2009).
135. Garey KW, Ghantoji SS, Shah DN et al. A randomized, double-blind, placebocontrolled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J. Antimicrob. Chemother. 66(12), 2850-2855 (2011).
136. Leach TS, Pullman J, Prieto J. Ramoplanin vs vancomycin in the treatment of C. difficile diarrhea: A Phase 2 study. Presented at 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 OctoberY2 November 2004 (Abstract K-985a).
137. Anderson VR, Curran MP. Nitazoxanide: A review of its use in the treatment of gastrointestinal infections. Drugs 67(13), 1947-1967 (2007). (Pubitemid 47347408)
138. Musher DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43(4), 421-427 (2006). (Pubitemid 44157148)
139. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin. Infect. Dis. 48(4), e41-e46 (2009).
140. Citron DM, Babakhani F, Goldstein EJ et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) Phase II study for C. difficile infection. Anaerobe 15(6), 234-236 (2009).
141. Whitman CB, Czosnowski QA. Fidaxomicin for the treatment of Clostridium difficile infections. Ann. Pharmacother. 46(2), 219-228 (2012).
142. Cornely OA, Crook DW, Esposito R et al.; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A doubleblind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12(4), 281-289 (2012).
143. Mullane KM, Miller MA, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53(5), 440-447 (2011).
144. Linsky A, Gupta K, Hermos JA. Fidaxomicin for Clostridium difficile infection. N. Engl. J. Med. 364(19), 1875; author reply 1875-1875; author reply 1876 (2011).
145. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch. Intern. Med. 170(9), 772-778 (2010).
146. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 58, 1062-1065 (2006)
147. Herpers BL, Vlaminckx B, Burkhardt O et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48(12), 1732-1735 (2009).
148. El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: A case report and review of the literature. Scand. J. Infect. Dis. 44(3), 228-230 (2012).
149. Kopterides P, Papageorgiou C, Antoniadou A et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth. Intensive Care 38(4), 755-758 (2010).
150. Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH Jr. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob. Agents Chemother. 52(6), 2190-2195 (2008). (Pubitemid 351758558)
151. Louie TJ, Gerson M, Grimard D et al. Results of a Phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD).Presented at: Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).Chicago, IL, USA, 17-20 September 2007 (Abstract K-4259).
152. Bouza E, Dryden M, Mohammed R et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in the treatment of Clostridium difficileassociated diarrhoea. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.
153. Weiss K. Toxin-binding treatment for Clostridium difficile: A review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 33(1), 4-7 (2009).
154. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).Vaccine 28(4), 965-969 (2010).
155. Sougioultzis S, Kyne L, Drudy D et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128(3), 764-770 (2005). (Pubitemid 40585378)
156. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30(13), 2245-2249 (2012).
157. Kelly CP, Pothoulakis C, Vavva F et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob. Agents Chemother. 40(2), 373-379 (1996). (Pubitemid 26049350)
158. Warny M, Fatimi A, Bostwick EF et al. Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44(2), 212-217 (1999). (Pubitemid 29119364)
159. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: A review. Dig. Dis. Sci. 56(1), 19-26 (2011).
160. Aldeyab MA, McElnay JC, Scott MG et al. An evaluation of the impact of a singledose intravenous immunoglobulin regimen in the treatment of Clostridium difficile infections. Infect. Control Hosp. Epidemiol. 32(6), 631-633 (2011).
161. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362(3), 197-205 (2010).
162. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst. Rev. 1, CD004611 (2008).
163. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271(24), 1913-1918 (1994). (Pubitemid 24177098)
164. Wullt M, Hagslätt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A doubleblind, placebo-controlled trial. Scand. J. Infect. Dis. 35(6-7), 365-367 (2003). (Pubitemid 37038627)
165. Miller M. The fascination with probiotics for Clostridium difficile infection: Lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 15(6), 281-284 (2009).
166. Muñoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: An emerging infectious disease. Clin. Infect. Dis. 40(11), 1625-1634 (2005). (Pubitemid 40720813)
167. Pozzoni P, Riva A, Bellatorre AG et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: A single-center, randomized, double-blind, placebo-controlled trial. Am. J. Gastroenterol. 107(6), 922-931 (2012).
168. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44(5), 854-859 (1958).
169. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1(8648), 1156-1160 (1989). (Pubitemid 19138849)
170. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53(10), 994-1002 (2011).
171. BilgramiS, Feingold JM, Dorsky D et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 23, 1039-1042 (1999). (Pubitemid 29250849)
172. Bignardi GE. Risk factors for Clostridium difficile infection. J. Hosp. Infect. 40, 1-15 (1998). (Pubitemid 28438966)
173. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin. Infect. Dis. 46, S4-11 (2008).
174. Barbut F, Corthier G, Charpak Y et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch. Intern. Med. 156, 1449-1454 (1996). (Pubitemid 26226940)
175. Thibault A, Miller MA, Gaese C et al. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect. Control Hosp. Epidemiol. 12, 345-348 (1991).
176. Gerding DN, Olsen MM, Peterson L et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch. Intern. Med. 146, 95-100 (1986). (Pubitemid 16158635)
177. Department of Health and Health Protection Agency. Clostridium difficile infection: How to deal with the problem. Centre of Innovation (2009).
178. Kuijper EJ, Coignard B, Tüll P et al. Emergence of clostidium difficile- associated disease in North America and Europe Clin. Microbiol. Infect. 12, 2-18 (2006). (Pubitemid 44362038)
179. Loo VG, Libman MD, Miller MA et al. Clostridium difficile: A formidable foe. CMAJ 71, 47-48 (2004). (Pubitemid 38925119)
180. McFarland LV, Surawicz CM, Stamm WE et al. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J. Infect. Dis. 162(3), 678-684 (1990). (Pubitemid 20266159)
181. Kuijper EJ, Barbut F, Brazier JS et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro. Surveill. 13ii, 18942 (2008).
182. Monaghan T, Boswell T, Mahida YR. et al. Recent advances in Clostridium difficileassociated disease. Gut 57, 850-860 (2008). (Pubitemid 351716982)
183. Dingle KE, Griffiths D, Didelot X et al. Clinical Clostridium difficile: Clonality and pathogenicity locus diversity. PLoS ONE 6(5), e19993 (2011).